WHO opens first clinical trial for Bundibugyo Ebola virus treatments
WHO-sponsored PARTNERS clinical trial enrolls first patient to test remdesivir and MBP134 for Bundibugyo Ebola, amid debate over Trump administration cuts to global health infrastructure.
Objective Facts
The PARTNERS trial enrolled its first patient on July 2, 2026, testing two antiviral candidates for the first time in history for Bundibugyo Ebola virus disease. The trial will assess whether the monoclonal antibody MBP134 and remdesivir can improve survival, and evaluate whether combining the two antivirals provides additional benefits. As of July 4, 2026, confirmed cases totaled 1,460 in DRC, 20 in Uganda, and 1 in France, with 454 deaths. The Africa CDC has appealed for $18 million to close a critical funding shortfall, with only $10 million of $26 million secured, leaving $16 million in post-exposure prophylaxis studies unfunded and $2-3 million for contact tracing. Regional media outlets in Africa emphasize the trial as a major scientific milestone led by DRC institutions and international partners, while also highlighting the ongoing resource constraints.
Left-Leaning Perspective
Senator Reverend Raphael Warnock and Democratic colleagues argued that the dismantling of USAID, withdrawal from WHO, and foreign aid cuts have degraded outbreak preparedness, and that the Trump Administration's withdrawal of global health funding has led to erosion of disease-monitoring infrastructure across Africa. Dr. Jade Le of Access TeleCare told CNBC that with the dismantling of USAID, funding cuts and pull-out from WHO, reductions in CDC workforce, and reduced health aid to the DRC, the Trump administration has certainly contributed to the delay in detection and lack of control of the outbreak. Democratic and mainstream left coverage treats the trial as a potential bright spot in an otherwise weakened response capacity.
Right-Leaning Perspective
Acting CDC Director Jay Bhattacharya, writing in The Wall Street Journal, defended the Trump administration's response by stating the measures being taken are scientifically justified, sensitive to the epidemiological facts, and specifically tailored to contain the outbreak, contrasting favorably with COVID-19 response measures that made little scientific sense. Bhattacharya denied that Trump administration cuts to foreign aid negatively impacted the global response, saying he has never met a more competent group of professionals than the CDC teams and has seen no evidence that cuts have impacted the ability to address outbreaks. The Washington Post editorial perspective stated it is not fair to place blame for the outbreak at the feet of the Trump administration, though the U.S. can choose to deploy its resources to help contain dangerous diseases.
Deep Dive
The WHO's launch of the PARTNERS clinical trial represents a genuine scientific milestone—the first formal attempt to test treatments specifically for Bundibugyo virus disease. The trial addresses a critical gap: while previous major Ebola outbreaks were caused by the Zaire strain (for which vaccines and monoclonal antibodies were developed and tested), Bundibugyo had caused only two previous small outbreaks (Uganda 2007, DRC 2012), leaving no approved therapeutics. The trial's immediate challenge is not scientific but operational: funding. The Africa CDC has identified a $16 million gap in its $26 million therapeutics portfolio, with only $10 million secured as of early July 2026. The political dimension centers on whether Trump administration decisions—specifically the dismantling of USAID in 2025 and withdrawal from WHO in early 2026—weakened the international disease surveillance infrastructure that historically provided early warning of outbreaks. Left-leaning sources point to concrete mechanisms: USAID-built laboratories, cold chain capacity, and surveillance networks in DRC that were funded or co-funded by the U.S. and became inactive when those programs ceased. They cite evidence that the Bundibugyo strain may have circulated undetected for 6-8 weeks before lab confirmation. Right-leaning sources, through CDC Director Jay Bhattacharya, contend that the U.S. response has been "scientifically justified" and adequate, noting that emergency funding mobilized ($107+ million from CDC, $23-270 million pledged by State Department) exceeds or matches historical spending on prior outbreaks. The key disagreement is not whether funding gaps exist—all sides acknowledge them—but whether they stem from policy choices versus resource prioritization, and whether emergency funds can meaningfully substitute for lost institutional capacity. What remains unresolved: whether the trial will enroll the target 1,200 patients quickly enough to generate statistically significant data while an outbreak is active in a war-torn region where insecurity and community mistrust are severe barriers. WHO officials warned that the outbreak continued to face major operational challenges, with mistrust within communities and ongoing violence remaining significant obstacles after an attack on an Ebola treatment centre in Ituri Province left two people dead. The trial's success depends partly on factors outside the control of either funding paradigm: whether DRC and Ugandan health authorities can build sufficient community trust to achieve enrollment targets, whether the rare virus will present enough clinical variation to test treatment efficacy, and whether geopolitical tensions over manufacturing access to MBP134 (a U.S.-government-owned product) or remdesivir will impede supply.
Regional Perspective
DRC Minister of Health Dr Samuel Roger Kamba stated the trial launch represents a significant step forward, offering renewed hope to patients, families, and affected communities, with findings that could contribute to identifying more effective therapeutic options and strengthening global preparedness. The Kenyan Standard Media and Nigerian Whistler emphasize the partnership structure, highlighting that the trial is sponsored by WHO and coordinated by DRC's INRB, Belgium's Institute of Tropical Medicine, and Oxford University, in collaboration with international research and humanitarian partners. This framing differs from Western coverage by centering DRC institutional agency rather than international response capacity or funding shortfalls. African business media (Nairametrics) reported that the DRC announced 1,561 confirmed cases and 506 deaths as the largest Bundibugyo outbreak on record, noting that although new daily infections have eased, transmission remains intense in Ituri Province, with international agencies warning the outbreak could inflict a heavy economic toll on Africa. Regional outlets emphasize the economic stakes (potentially $1 billion in lost GDP for DRC) and security challenges (insecurity in war-torn Ituri) more explicitly than Western coverage, framing the trial within the broader humanitarian crisis context. The Eastern Herald noted that Marburg virus was simultaneously detected in western Uganda in a toddler, introducing a second hemorrhagic fever into a health system already stretched by Ebola, creating diagnostic complications because both diseases share early symptoms and distinguishing between them requires rapid testing not always available in rural clinics. This regional analysis emphasizes overlapping epidemic threats and diagnostic capacity constraints that Western media coverage largely overlooked, reflecting the on-the-ground reality of affected countries.